Browse by Vaccine Type

This page shows data for RNA based vaccine vaccine type.
Total Entries Retrieved: 40
IDVaccine NameDisease NameDisease ClassificationVirus NameNucleic Acid ContentVaccine TypeVaccine StatusManufacturerYear of ManufacturingManufacturing CountryAgeDosageAdministration RouteAdjuvantTarget StrainDescriptionApproving OrganisationCollaborating OrganisationOther CountriesTrade NamePMIDClinical Trial IDReference LinkAdditional Links
10001 Spikevax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved Moderna Inc. 2020 USA 18 years and above 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus mRNA based vaccine US FDA NA USA, Canada, UK, Netherlands, Denmark, Germany, Switzerland mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran NA NCT04969250 https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/spikevax-and-moderna-covid-19-vaccine NA
10014 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved AstraZeneca plc, University of Oxford, Serum Institute of India 2020 England NA NA Intramuscular NA NA mRNA based vaccine European Inclusive Vaccines Alliance NA UK, USA, Brazil, South Africa AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria 33324769 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729279/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637436/
10024 Comirnaty COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved BioNTech SE, Pfizer Inc. NA Germany 18 - 85 years NA Intramuscular NA SARS-CoV-2 spike protein mRNA encapsulated in a lipid nanoparticle NA US FDA NA USA, Argentina, Brazil, Germany, South Africa, Turkey BNT162b2, COVID-19 mRNA vaccine, Tozinameran 32328406 NA https://pubmed.ncbi.nlm.nih.gov/32328406/ https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf
10025 Comirnaty COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved BioNTech SE, Pfizer Inc. 2021 Germany, USA NA NA Intramuscular NA NA mRNA based vaccine US FDA NA NA BNT162b2, COVID-19 mRNA vaccine 33610448 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881713/ NA
10026 Comirnaty COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved BioNTech SE, Pfizer Inc. NA USA 12 years and above 2 doses 3 weeks apart Intramuscular NA Trimerized SARS-CoV-2 receptor-binding domain from spike protein mRNA based vaccine US FDA NA Argentina, Canada, Chile, Costa Rica, Ecuador, Jordan, Kuwait, Mexico, Panama, Singapore, Bahrain, Saudi Arabia, Switzerland, European Union BNT162b2, COVID-19 mRNA vaccine, Tozinameran 33826439 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040490// https://www.comirnaty.com/
10027 Spikevax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved Moderna Inc. 2020 USA NA 2 doses Intramuscular NA SARS-CoV-2 spike protein mRNA encapsulated in a lipid nanoparticle NA US FDA NA NA mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran 32328406 NA https://pubmed.ncbi.nlm.nih.gov/32328406/ https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Moderna.html
10028 Spikevax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved Moderna Inc. NA NA NA 2 doses 28 days apart Intramuscular NA NA NA US FDA National Institute of Allergy and Infectious Diseases NA mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10029 Spikevax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved Moderna Inc. NA NA NA 2 doses 4 weeks apart Intramuscular NA NA NA US FDA NA USA, Canada, Israel, European Union mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran 33826439 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040490/ NA
10035 Comirnaty COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved BioNTech SE, Pfizer Inc. 2020 Germany 18 - 55 years 2 doses 21 days apart Intramuscular NA Trimerized SARS-CoV-2 receptor-binding domain from spike protein mRNA based vaccine US FDA NA Argentina, Brazil, Germany, South Africa, Turkey, USA BNT162b2, COVID-19 mRNA vaccine 33402220 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ NA
10036 Spikevax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved Moderna Inc. 2020 USA 18 - 55 years 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus mRNA based vaccine US FDA NA NA mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran 33402220 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ NA
10043 Comirnaty COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved BioNTech SE, Pfizer Inc. 2021 Germany, USA NA NA Intramuscular NA NA mRNA based vaccine US FDA NA NA BNT162b2, COVID-19 mRNA vaccine NA NA https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf https://www.who.int/publications/m/item/comirnaty-covid-19-mrna-vaccine#:~:text=Pfizer%2DBioNTech%20COVID%2D19%20Vaccine%2C%20COMIRNATY%C2%AE%20(Tozinameran),-COVID%2D19%20Vaccine&text=This%20vaccine%20resource%20provides%20key,disease%20(COVID%2D19).
10047 Spikevax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved Moderna Inc. 2020 USA NA NA Intramuscular NA NA mRNA based vaccine EMA NA NA mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran NA NA https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf NA
10166 ChulaCov19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Chulalongkorn University NA NA NA 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10173 SARS-CoV-2 mRNA vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Shulan (Hangzhou) Hospital NA NA NA 2 doses 14 days apart Intramuscular NA NA NA NA Guangxi CDC NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10174 LNP-nCoVsaRNA COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Imperial College London 2021 UK 18 - 75 years 2 doses Intramuscular NA Self-amplifying RNA SARS-CoV-2 lipid nanoparticle NA NA NA NA COVAC1 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10181 PTX-COVID19-B COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Providence Therapeutics Holdings Inc. 2021 Canada 18 - 64 years 2 doses 28 days apart Intramuscular NA NA NA NA NA NA NA NA NCT04765436 https://clinicaltrials.gov/show/NCT04765436 NA
10187 Spikevax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Moderna Inc. 2021 USA 18 years and above 2 doses 28 days apart Intramuscular NA NA mRNA based vaccine US FDA NA NA mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran NA NCT04785144 https://clinicaltrials.gov/ct2/show/NCT04785144 NA
10192 CoV2 SAM COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 GlaxoSmithKline 2021 USA 18 - 50 years 2 doses 1 month apart Intramuscular NA Spike protein of SARS-CoV-2 virus mRNA based vaccine NA NA NA NA NA NCT04758962 https://clinicaltrials.gov/ct2/show/study/NCT04758962 NA
10194 ChulaCov19 mRNA vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Chulalongkorn University 2021 Thailand 18 - 75 years 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04566276 https://clinicaltrials.gov/show/NCT04566276 NA
10213 GSK HSV Vaccine Genital Herpes Cutaneous Herpes simplex virus double stranded DNA RNA based vaccine Phase 1 GlaxoSmithKline 2021 UK 18 - 40 years 2 doses at interval of 2 months Intramuscular NA Herpes simplex virus 2 glycoprotein D (gD-2) mRNA based vaccine US FDA NA NA NA NA NA https://www.precisionvaccinations.com/vaccines/herpes-vaccine-candidates https://www.precisionvaccinations.com/vaccines/hsv-2-vaccine-gsk4108771a#:~:text=The%20herpes%20simplex%20virus%20type,genetic%20code%20of%20a%20virus.
10221 CHKV-24 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 NA NA NA NA Single dose Intravenous NA NA NA NA NA NA NA 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA
10229 mRNA-1944 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Moderna Inc. 2021 USA 18 - 50 years NA NA NA CHIKV-directed monoclonal antibody NA US FDA Defense Advanced Research Projects Agency NA NA NA NCT03829384 https://link.springer.com/chapter/10.1007/82_2019_175 https://clinicaltrials.gov/ct2/show/NCT03829384
10230 mRNA-1388 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Moderna Inc. 2017 USA 18 - 49 years 3 doses on week 0, week 4, post 1 year Intramuscular NA CHIKV structural proteins mRNA based vaccine NA Defense Advanced Research Projects Agency NA NA NA NA https://link.springer.com/chapter/10.1007/82_2019_175 https://www.modernatx.com/pipeline/mrna-1388
10232 VAL-181388 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Moderna Inc. 2017 USA 18 - 49 years 3 doses on week 0, week 4, post 1 year NA NA NA NA US FDA Defense Advanced Research Projects Agency NA NA NA NCT03325075 https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919 https://clinicaltrials.gov/ct2/show/NCT03325075
10238 BG505 mRNA Acquired Immunodeficiency Syndrome (AIDS) Other Human Immunodeficiency Virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 National Institute of Allergy and Infectious Diseases 2022 USA 18 - 55 years NA Intramuscular NA BG505 MD39 mRNA NA NA National Institutes of Health NA NA NA NCT05217641 https://clinicaltrials.gov/ct2/show/NCT05217641 https://www.nih.gov/news-events/news-releases/nih-launches-clinical-trial-three-mrna-hiv-vaccines
10244 HGCO19 (COVID-19 vaccine) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 Gennova Biopharmaceuticals Limited 2020 India 18 years and above NA Intramuscular NA Spike protein of SARS-CoV-2 virus mRNA based vaccine NA HDT Biotech Corporation NA HGCO19 (COVID-19 vaccine) NA NA https://gennova.bio/mrna-vaccines/ https://vaccine.icmr.org.in/covid-19-vaccine
10248 EXG-5003 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 Elixirgen Therapeutics Inc. 2021 Japan 20 - 55 years NA Intradermal NA NA mRNA based vaccine NA NA NA NA NA NCT04863131 https://clinicaltrials.gov/show/NCT04863131 NA
10249 BNT162a1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 BioNTech SE, Pfizer Inc. NA NA NA NA Intramuscular NA SARS-CoV-2 spike protein mRNA encapsulated in a lipid nanoparticle NA NA NA NA BNT162b1, BNT162b2, BNT162c2 32585611 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301105/ NA
10252 DS-5670a COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 Daiichi Sankyo Co. Ltd. 2021 Japan 20 - 74 years 2 doses Intramuscular NA NA mRNA based vaccine NA NA NA NA NA NCT04821674 https://clinicaltrials.gov/ct2/show/NCT04821674 NA
10258 LUNAR-COV19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 Arcturus Therapeutics 2021 Singapore NA 2 doses 28 days apart Intramuscular NA Self-replicating RNA mRNA based vaccine NA NA NA SARS-CoV-2 vaccine, ARCT-021 33816047 NCT05037097 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10273 Comirnaty COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 BioNTech SE, Pfizer Inc. 2020 NA 18 - 55 years 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus mRNA based vaccine US FDA NA NA BNT162b2, COVID-19 mRNA vaccine 33402220 NCT04368728 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ https://clinicaltrials.gov/ct2/show/NCT04368728
10283 MRT5500 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 Sanofi Pasteur, Translate Bio 2021 USA 18 years and above 2 doses 28 days apart Intramuscular NA NA mRNA based vaccine US FDA NA NA VAW00001 NA NCT04847050 https://www.clinicaltrials.gov/ct2/show/NCT04847050 NA
10320 CVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 CureVac AG 2021 Belgium 18 years and above 2 doses 28 days apart Intramuscular NA NA NA NA NA NA NA NA NCT04860258 https://clinicaltrials.gov/ct2/show/NCT04860258?term=NCT04860258&draw=2&rank=1 NA
10323 BNT162b1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 BioNTech SE, Pfizer Inc. NA NA NA 2 doses 28 days apart Intramuscular NA NA NA NA NA NA NA 33816047 NCT04368728 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://clinicaltrials.gov/ct2/show/NCT04368728
10324 INO-4800 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 Inovio Pharmaceuticals 2021 USA 18 years and above 2 doses 28 days apart Intradermal NA Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA 32328406 NA https://pubmed.ncbi.nlm.nih.gov/32328406/ https://ir.inovio.com/news-releases/news-releases-details/2021/INOVIO-Further-Expands-INNOVATE-Phase-3-Trial-for-COVID-19-DNA-Vaccine-Candidate-INO-4800-With-Regulatory-Authorization-from-India/default.aspx
10331 CVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 CureVac AG 2021 Belgium 18 years and above 2 doses 28 days apart Intramuscular NA SARS-CoV-2 receptor-binding domain from spike protein mRNA based vaccine NA NA NA CVnCoV 33816047 NCT04860258 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10334 AWcorna COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 Academy of Military Sciences, Walvax Biotechnology Co. Ltd. 2021 China 18 years and above 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus mRNA based vaccine NA NA NA Walvax COVID-19 vaccine, ARCoV NA NCT04847102 https://delta.larvol.com/products/?ProductId=4355caae-8746-469c-ab52-0b40ddfde811&Index=0 NA
10335 ARCT-154 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 Vinbiocare Biotechnology Joint Stock Company 2021 Vietnam 18 years and above 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA Arcturus Therapeutics Inc. NA VBC-COV19-154 NA NCT05012943 https://clinicaltrials.gov/ct2/show/NCT05012943 NA
10344 CVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 CureVac AG NA Germany NA NA Intramuscular NA NA mRNA based vaccine NA NA Germany, Cuba, Peru CVnCoV NA NCT04674189 https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf https://clinicaltrials.gov/ct2/show/NCT04674189
10375 OMB157 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 4 Novartis 2021 Germany 18 years and above NA Subcutaneous NA NA NA NA NA NA Ofatumumab NA NCT04869358 https://clinicaltrials.gov/show/NCT04869358 https://www.ema.europa.eu/en/documents/assessment-report/kesimpta-epar-public-assessment-report_en.pdf